EFFicacy Optimization Research of Telbivudine Therapy (EFFORT)
A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study)
Sponsor: Major Science and Technology Special Project of China Eleventh Five-year
A PHASE4 clinical study on Hepatitis B, Chronic, this trial is completed. The trial is conducted by Major Science and Technology Special Project of China Eleventh Five-year and has accumulated 7 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2023 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Aug 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Major Science and Technology Special Project of China Eleventh Five-year
- Nanfang Hospital, Southern Medical University
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Jinan, China , Nanjing, China , Shanghai, China and 3 more locations